Free Access
| Issue |
Med Sci (Paris)
Volume 40, Novembre 2024
Les Cahiers de Myologie
|
|
|---|---|---|
| Page(s) | 22 - 25 | |
| Section | Prix SFM | |
| DOI | https://doi.org/10.1051/medsci/2024132 | |
| Published online | 18 November 2024 | |
- Barraud C, Desguerre I, Barnerias C, et al. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve 2018 ; 57 (4) : 603–609. [CrossRef] [PubMed] [Google Scholar]
- Anlar B. Juvenile Myasthenia. Paediatr Drugs 2000 ; 2 (3) : 161–9. [CrossRef] [PubMed] [Google Scholar]
- Zingariello CD, Elder ME, Kang PB. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Pediatr Neurol 2020 ; 111 : 40–43. [CrossRef] [PubMed] [Google Scholar]
- Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2020 ; 96 (3) : 114–122. [Google Scholar]
- Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol 2020 ; 77 (8) : 974–981. [CrossRef] [PubMed] [Google Scholar]
- Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 ; 6 (5 Pt 1) : 859–866. [CrossRef] [PubMed] [Google Scholar]
- Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017 ; 89 (10) : 1069–1077. [CrossRef] [PubMed] [Google Scholar]
- Fichtner ML, Jiang R, Bourke A, et al. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front Immunol 2020 ; 11 : 776. [CrossRef] [PubMed] [Google Scholar]
- Hachiya Y, Uruha A, Kasai-Yoshida E, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol 2013 ; 265 (1-2) : 128–130. [CrossRef] [PubMed] [Google Scholar]
- McAtee CL, Lubega J, Underbrink K, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open 2021 ; 4 (2) : e2036321. [CrossRef] [PubMed] [Google Scholar]
- Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 2022 ; 79 (11) : 1105–1112. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.